510(k) device
Vidas Troponin I Ultra (Tniu) Assay, Model 30 448
bioMerieux, Inc. · Immunoassay Method, Troponin Subunit (MMI, Class II) · First FDA decision Jun 16, 2003, newest Dec 14, 2007Heart attack (myocardial infarction)Heart attack and heart failure blood tests
Last checked: Nov 21, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
510(k) pathway
Device trials
3
Naming "Vidas"
MAUDE reports
1,216
Brand "Vidas", since 2015
PubMed studies
825
Mentioning "Vidas"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Vidas Troponin I Ultra (Tniu) Assay, Model 30 448
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
K063243 · Decided Dec 14, 2007 · 414 days after receipt
Device type: Immunoassay Method, Troponin Subunit (MMI) · Laboratory Medicine & Pathology
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Vidas", any status and sponsor, newest update first.
BioMérieuxNot on our public-company list
NCT06037109 · 585 participants · Start Jul 18, 2023 · Primary completion Dec 28, 2023
Device: Diagnostic Test: VIDAS® NEPHROCLEAR™ CCL14 Test · For: Healthy
Sites: Washington D.C., District of Columbia; Chicago, Illinois
2 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Vidas", and for the whole product code for context.
This brand
1,216 reports: 1,150 malfunction, 64 injury, 1 death
Whole product code MMI
7,546 reports: 7,009 malfunction, 528 injury, 4 death
Newest reports for this brand
- VIDAS®3 [U]Malfunction
9615037-2026-00009 · Received Oct 8, 2026
Device type: Analyzer, Chemistry (Photometric, Discrete), For Clinical Use (JJE)
Device problem as coded: Appropriate Device Problem Term/Code Not Available
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Vidas"[tiab]. The summary above synthesizes these.
- [Not Available].
Lazcano-Ponce E · Salud Publica Mex · 2023English Abstract
- Performance Characteristics of the Vidas SARS-CoV-2 IgM and IgG Serological Assays.
Renard N, Daniel S, Cayet N, et al. · J Clin Microbiol · 2021Research Support, Non-U.S. Gov't
- Evaluation of the bioMérieux VIDAS HIV Duo Quick and Anti-HCV assays for dried blood spot based serosurveillance.
Cholette F, Farmer B, Balakireva O, et al. · Sci Rep · 2022Research Support, Non-U.S. Gov't
- Performance Evaluation of VIDAS® Diagnostic Assays Detecting Anti-Chikungunya Virus IgM and IgG Antibodies: An International Study.
Pereira GM, Manuli ER, Coulon L, et al. · Diagnostics (Basel) · 2023
- Comparison between qPCR, VIDAS immunoassays, and agar streaking for the detection of Listeria monocytogenes from food and environmental surfaces containing and not containing Listeria innocua.
Xian Z, Yoo J, Patel C, et al. · J Food Prot · 2023Research Support, U.S. Gov't, P.H.S.
- VIDAS Listeria monocytogenes II (LMO2).
Johnson R, Mills J · J AOAC Int · 2013
- Viral protease-initiated lytic cell death as a universal antiviral mRNA therapy.
Li L, Yan XL, Wang HY, et al. · Cell · 2026
- Accuracy of VIDASⓇ TB-IGRA in TB patients and individuals with different thresholds of exposure.
Goletti D, Banaei N, Batra R, et al. · Int J Infect Dis · 2026Multicenter Study
- Performance characteristics of the VIDAS® ANTI-HEV IgM and IgG assays.
Abravanel F, Goutagny N, Joffray R, et al. · J Clin Virol · 2019Evaluation Study, Research Support, Non-U.S. Gov't
- Performance Evaluation of the VIDAS® D-Dimer Exclusionࡊ II Assay and the Beckman Coulter D-Dimer Assay.
Yen KT, Jiang JF, Chen CC, et al. · Clin Lab · 2023Letter
- VIDAS® TB-IGRA reagents induce a CD4+ and CD8+ T-cell IFN-γ response for both TB infection and active TB.
Petruccioli E, Farroni C, Cuzzi G, et al. · Int J Tuberc Lung Dis · 2022Letter
- Evaluation of the VIDAS Cytomegalovirus (CMV)-IGRA for Assessing CMV-Specific T-Cell Responses in Immunocompetent and Immunosuppressed Individuals.
Giménez E, Albert E, Colomer E, et al. · J Med Virol · 2025Evaluation Study, Comparative Study
Other devices of this type
Also filed under product code MMI.
- Access hsTnIBeckman Coulter, Inc. · 510(k) 2025
- Elecsys Troponin T Gen 5Roche Diagnostics · 510(k) 2021
- i-STAT hs-TnI cartridge with the i-STAT Alinity SystemAbbott Point of Care, Inc. · 510(k) 2026
- VITROS Immunodiagnostic Products hs Troponin I Reagent PackOrtho-Clinical Diagnostics, Inc. · 510(k) 2025
- Atellica® IM High-Sensitivity Troponin I (TnIH)Siemens Healthcare Diagnostics, Inc. · 510(k) 2024
- Alinity i STAT High Sensitivity Troponin-IAbbott Laboratories Diagnostics Division · 510(k) 2023
- Dimension Vista Ctni Flex Reagent CartridgeDade Behring, Inc. · 510(k) 2007
- Abbott Axsym Troponin-I AdvAbbott Laboratories · 510(k) 2006
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.